Sugi Predict

Sugi Predict / Compounds / SCHEMBL3305019

SCHEMBL3305019

SCHEMBL3305019

OCc1cc(Br)cc(OC(F)(F)F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.40
▸ USP28 Q96RU2 1/20 0.36
▸ USP25 Q9UHP3 1/20 0.36
▸ EPAS1 Q99814 1/20 0.35
▸ CYP4F2 P78329 1/20 0.34
▸ CYP4A11 Q02928 1/20 0.34
▸ CETP P11597 2/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ PGR P06401 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ SLC6A4 P31645 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089811 0.86 FFAR4 (0.44) FFAR4CYP4F2CYP4A11CETPGRIN2B
SCHEMBL27377026 0.86 USP28 (0.38) FFAR4USP28USP25CYP4F2CYP4A11
SCHEMBL16726974 0.85 GRIN2B (0.34) USP28USP25CETPGRIN2BPGR
SCHEMBL30986226 0.83 CETP (0.35) FFAR4USP28USP25CETPGRIN2B
SCHEMBL12886690 0.83 PGR (0.36) USP28USP25CETPGRIN2BPGR
SCHEMBL22090574 0.83 CETP (0.35) FFAR4USP28USP25CETPGRIN2B
SCHEMBL22089768 0.81 IDO1 (0.38) USP28USP25CETPGRIN2BPGR
SCHEMBL12160006 0.80 PGR (0.39) PGRCA1CA2CA7CA9
SCHEMBL1510479 0.80 PGR (0.39) PGRCA1CA2CA7CA9
SCHEMBL16959216 0.79 FFAR4 (0.43) FFAR4CYP4F2CYP4A11CETPGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 — — US disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 — — EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 — — US disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 — — US disclosed
WO-2022185041-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2022-09-09 — — WO disclosed
EP-2935249-B1 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2018-12-12 — — EP disclosed
EP-2086982-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 — — EP disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 — — US disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 — — US disclosed
US-9738661-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-22 — — US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 — — US disclosed
US-20150266897-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2015-09-24 — — US disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 — — EP disclosed
WO-2014097151-A2 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2014-06-26 — — WO disclosed
US-20140171404-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2014-06-19 — — US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 — — US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 — — US disclosed
US-20100099695-A1 HCV NS3 Protease Inhibitors MSD ITALIA S.R.L. (IT) 2010-04-22 — — US disclosed
CN-101611039-A HCV NS3 protease inhibitors MERCK & CO INC (US) 2009-12-23 — — CN disclosed
WO-2008057209-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099695-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC FFAR4 4165/4885USP28 347/4885USP25 336/4885
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 FFAR4 4365/4885USP28 2788/4885USP25 3145/4885
US-20150266897-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC FFAR4 4165/4885USP28 347/4885USP25 336/4885
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof ABCB11, CEL, NDC1 FFAR4 1949/4885USP28 4368/4885USP25 4339/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 FFAR4 4365/4885USP28 2788/4885USP25 3145/4885
US-20140171404-A1 Autotaxin inhibitors ENPP2, ATXN10, ATXN2L FFAR4 4514/4885USP28 628/4885USP25 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.